Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI)
$2.2200
+0.0800 ( -1.77% ) 40.2K
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Market Data
Open
$2.2200
Previous close
$2.1400
Volume
40.2K
Market cap
$13.52M
Day range
$2.1800 - $2.2940
52 week range
$1.0500 - $11.8905
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 54 | Nov 14, 2024 |
8-k | 8K-related | 14 | Nov 14, 2024 |
8-k | 8K-related | 14 | Oct 30, 2024 |
4 | Insider transactions | 1 | Oct 02, 2024 |
8-k | 8K-related | 14 | Oct 01, 2024 |
8-k | 8K-related | 43 | Oct 01, 2024 |
8-k | 8K-related | 13 | Sep 26, 2024 |
8-k | 8K-related | 16 | Sep 16, 2024 |
ars | Annual reports | 1 | Aug 16, 2024 |
def | Proxies and info statements | 5 | Aug 16, 2024 |